INTRODUCTION
A lternatives to whole-animal testing of environmental and industrial chemicals are needed for understanding the toxicity potential of the many thousands of chemicals and materials in commercial use. Cost, animal welfare concerns, and relevance to human risk are the major issues driving this need. The US Environmental Protection Agency (EPA) has initiated a large-scale effort, ToxCast, which is investigating high-throughput, in vitro assays as a means to develop predictive toxicology models. The goal of the project is to compose broad bioactivity profiles characterizing the in vitro biological activity of a reference set of chemicals. 1 These profiles will be correlated with in vivo toxicity endpoints culled from extensive in vivo animal studies, including those used for pesticide registration submissions to the EPA (e.g., chronic toxicity endpoints). 2 Generation of bioactivity profiles for chemicals lacking toxicity information and analysis of similarity to reference chemicals would then be applied to predict potential for toxicity. The ultimate goal is to provide an efficient means to prioritize for detailed study the approximately 10,000 industrial and environmental chemicals of potential concern for which minimal toxicity data currently exist. 3 One important focus of the ToxCast project is measuring the chemical perturbation of critical cellular signaling pathways that may represent potential modes of chemical toxicity. This is being accomplished using in vitro bioactivity profiles derived from screening the ToxCast chemical library against both specific molecular targets using high-throughput, biochemical screening assays, as well as testing in a large suite of cellular assays. One such cellular system that characterizes pharmaceutical drug function is based on statistical analysis of protein expression in a panel of assays using primary human cells stimulated in complex environments. This approach, called Biologically Multiplexed Activity Profiling (BioMAP), provides characterization of drug function across a broad range of tissue and disease biology. The pattern of activity in these systems allows classification of molecules according to mechanism of action, possibly providing insights into clinical phenomena. [4] [5] [6] The cell systems contain primary human cells in different environments relevant to vascular inflammation and immune activation. BioMAP profiling has been shown to detect and discriminate multiple functional drug classes, including glucocorticoids, tumor necrosis factor-alpha (TNF-α) antagonists, and inhibitors of calcineurin, HMG-CoA reductase, heat shock protein 90, inosine monophosphate dehydrogenase, phosphodiesterase 4, phosphoinositide kinase-3, and p38 mitogen-activated kinase, among others. [4] [5] [6] BioMAP systems are designed to model complex human disease and tissue biology by stimulating human primary cells, single cell type, or defined mixtures of cell types, such that multiple disease-and tissue-relevant signaling pathways are simultaneously active. The choice of cell types and stimulations is guided by knowledge of relevant disease biology and mechanisms. Chemical effects are then recorded by measuring biologically meaningful protein readouts relevant to significant biological responses (e.g., inflammation, tissue remodeling). [4] [5] [6] [7] Activity profiling in BioMAP systems, in conjunction with BioSeek's database that contains profiles of hundreds of experimental pharmaceutical compounds and approved therapeutics, provided one interpretation of potential modes of toxicity. The primary goal of the present study was to generate BioMAP profiles that could then be used as part of the entire ToxCast in vitro data set for classifying environmental chemicals in the ToxCast database based on predictive signatures and putative toxicity pathways.
MATERIALS AND METHODS

Cell culture
BioMAP systems employed are shown in Table 1 . Preparation and culture of endothelial cells and methods for the 3C, 4H, LPS, and SAg systems were as previously described. 4, 5 Human neonatal foreskin fibroblasts (HDFn) from 3 donors were pooled and cultured according to the supplier's (Lonza, Inc., Allendale, NJ) recommendation. HDFn were plated in low serum conditions 24 h before stimulation with cytokines. Primary human bronchial epithelial cells (Cell Applications, Inc., San Diego, CA), arterial smooth muscle cells (Lonza, Inc.), and keratinocytes (Cambrex, Inc., East Rutherford, NJ) were cultured according to methods recommended by the commercial suppliers. Peripheral blood mononuclear cells (PBMCs) were prepared from buffy coats from normal human donors. 5 Concentrations/amounts of agents added to confluent microplates to build each system were as follows: cytokines (IL-1β, 1 ng/mL; TNF-α, 5 ng/mL; IFN-γ, 20 ng/mL; IL-4, 5 ng/mL), activators (histamine, 10 µM; SAg, 20 ng/mL; or LPS, 2 ng/mL), growth factors (TGF-β, 5 ng/mL; EGF, bFGF, and PDGF-BB, 10 ng/mL), or PBMC (7.5 × 10 4 cells/well). All primary human cells used in this work were obtained via commercially available sources.
Compounds
Compounds were tested at 40, 13.3, 4.4, and 1.48 µM for the study, in a single well per readout parameter. Compounds were prepared in DMSO from 20-mM stock solutions, added 1 h before stimulation of the cells, and were present during the whole 24-h stimulation period. Final DMSO concentration was 0.2%. Colchicine, 3.3 µM, was included as a positive control. Compounds were tested in a blinded fashion and included 3 sets of triplicate samples and 5 sets of duplicates for quality control purposes.
Plate formats. Templates were prepared with 7 compounds (4 concentrations) per 96-well plate. One positive control (colchicine) and 8 negative control wells (0.2% DMSO) were employed on each plate. Left and rightmost rows (A1-H1, A12-H12) were not employed for EPA compounds.
ELISA
The levels of readout parameters were measured by enzymelinked immunosorbent assay (ELISA) as described. 8 Briefly, microplates were treated, blocked, and then incubated with primary antibodies or isotype control antibodies (0.01-0.5 µg/ mL) for 1 h. After washing, plates were incubated with a peroxidase-conjugated antimouse IgG secondary antibody or a biotin-conjugated antimouse IgG antibody for 1 h followed by streptavidin-horseradish peroxidase (HRP) for 30 min. Plates were washed and developed with tetramethylbenzidine (TMB) substrate, and the absorbance (OD) was read at 450 nm (subtracting the background absorbance at 650 nm). Quantitation of TNF-α and PGE2 in the LPS system was done using commercially available kits according to the manufacturer's directions. Proliferation of PBMC (T cells) was quantified by Alamar blue reduction, and proliferation of adherent cell types was quantified by sulforhodamine B (SRB) staining. 9
Other assessments
Overtly adverse effects of compounds on cells were determined by (1) measuring alterations in total protein (SRB assay), (2) measuring the viability of peripheral blood mononuclear cells, and (3) microscopic visualization. SRB was performed by staining cells with 0.1% sulforhodamine B after fixation with 10% trichloroacetic acid (TCA) and reading wells at 560 nm. PBMC viability was assessed by adding Alamar blue to PBMC that had been cultured for 24 h in the presence of activators and compounds and measuring its reduction after 8 h. Samples were assessed visually according to the following scheme: 2.0 = cobblestone (unactivated phenotype), 1.0 = activated (normal phenotype), 0.5 = lacy or sparse, 0.375 = rounded, 0.25 = sparse and granular, and 0.1 = no cells in well. During this procedure, cells were also assessed for the presence of compound precipitates, and samples were flagged if precipitates were observed.
Data analysis
Measurement values for each parameter in a treated sample were divided by the mean value from 6 DMSO control samples (from the same plate) to generate a ratio. All ratios were then log 10 transformed. Visual categorical scores (see above) were similarly converted (log 10 ratios of 0.3, 0.0, -0.3, -0.4, -0.6, and -1.0). Significance prediction envelopes were calculated for historical controls (99% and 95%). Hit prediction envelopes (99% and 95%) were also calculated from historical controls. Hit prediction envelopes differ from significance envelopes in that they are calculated for the entire profile, not for individual readout parameters. Thus, a 95% hit envelope will contain 95% of control profiles and therefore will depend on the specific systems and readouts selected for analysis. 10, 11 Overtly cytotoxic compounds are identified as generating profiles with one or more of the following readouts below the indicated thresholds: SRB <-0.3, PI or PBMC cytotoxicity <-0.1, or visual score <-0.6 in 1 or more systems. The complete set of results for the 320 chemicals for each of the 87 endpoints can be accessed at http://www.epa.gov/ncct/toxcast/.
For analysis of profile similarities, overtly cytotoxic compound profiles were removed. The correlation metric was a combination of similarity metrics in addition to Pearson's correlation (J. Yang and E. Berg, personal communication, 2008) . This approach was found to improve the accuracy of mechanism classification with test data sets (not shown), due to the diversity of BioMAP profile characteristics (wide variation in the number of active readouts, the number of active systems, and the amplitude of biomarker readout changes). Thus, the similarity metrics used for the analyses of profiles included Pearson's correlation, a real-value Tanimoto metric (= A⋅B/(||A|| + ||B|| -A⋅B, where A and B are the 2 profile vectors), and a system weighted-averaged real-value Tanimoto metric (= Σ (i = system) Wi⋅Ti/ΣWi, where Ti is the real-value Tanimoto score for the ith system, Wi is the weight for the ith system, and Wi is the number of markers in the system/(1 + exp[-(max.ratio of the 2 profiles in this system -0.09)⋅100]). The real-value Tanimoto metric was employed as a scaled version for filtering profile similarities. The scaled version is calculated by normalizing each profile to the unit vector (e.g., A = A/||A||) first, then applying the formula given above.
Table 1. Eight BioMAP Systems Used in This Study
BioMAP Systems listed according to their short names comprise the cell types shown cultured and stimulated with the environmental factors (added along with test compounds) for 24 h. For each system, the biomarker readouts listed (number of readouts is shown in parentheses) are measured at 24 or 72 h, as described in Materials and Methods.
Similar profiles were identified as those having Pearson correlations >0.7 and Tanimoto scores >0.5 (or as otherwise indicated). Thresholds for these metrics were set using specific sets of training and test sets of profile data (not shown). The function similarity map uses the results of pairwise correlation analysis to project the "proximity" of related profiles from multidimensional space to 2 dimensions. The 2-dimensional projection coordinates were generated by applying a modified nonlinear mapping technique, using a modified stress function by Clark. A gradient descent minimization method was used to minimize the modified stress function, starting from a set of initial positions (e.g., from principal components analysis). Distances between compounds are representative of their similarities, and lines are drawn between compounds whose profiles are sufficiently similar, with metrics that are above all selected thresholds (passing all filters).
RESULTS
Overview of ToxCast compound activities in BioMAP systems
In total, 320 ToxCast proof-of-concept chemicals (list available at http://www.epa.gov/ncct/toxcast/) were tested in 8 BioMAP model systems ( Table 1 ) at 4 concentrations, from 1.3 to 40 µM. In each assay system, 7 to 14 biomarker readouts were measured for a total of 87 readout measurements per compound per concentration tested. Active compounds were identified as those compounds for which biomarker readout changes at 1 or more concentrations resulted in the overall compound profile appearing outside of a 95% hit prediction envelope (developed from replicates of negative control sample replicates; see Materials and Methods). Of the 320 compounds tested, 219 (68%) were active, based on these criteria. The complete BioMAP data set for the ToxCast chemicals can be accessed at http://www.epa.gov/ncct/ toxcast/.
Cytotoxicity of ToxCast compounds in BioMAP systems
Each BioMAP system ( Table 1 ) contains 1 or more assay endpoints that correlate with overt cell cytotoxicity. Such cytotoxicity may confound interpretation of mechanistic information by causing changes in biomarker levels through effects secondary to cell death. Thus, concentrations of chemicals inducing significant cytotoxicity were excluded from further analysis. These cytotoxicity endpoints include SRB staining for total protein, Alamar blue assessment of peripheral blood mononuclear cell metabolic activity (PBMC Cytotox.), and a morphologic score (Vis). The Vis score classifies cell shape as defined in Materials and Methods. Cytotoxicity of compounds can depend on cell type as well as the cellular environment. Compound exposures that resulted in a >50% reduction in total protein levels (log ratio 10 of SRB ≤0.3) were considered overtly cytotoxic, and by this criterion, 70 ToxCast compounds were cytotoxic to at least 1 cell type at 1 or more concentrations. Figure 1 shows the distribution of cytotoxicities (indicated by red) by cell type (system) and concentration. Cell type-selective cytotoxicities were observed with a number of compounds; for example, metiram-zinc was cytotoxic to PBMC and fibroblast-containing systems but not endothelial cells, and perfluorooctane sulfonic acid was selectively cytotoxic to epithelial cells. Of the compounds exhibiting overt cytotoxicity, these were most frequently cytotoxic to endothelial cells (3C system) and least frequently cytotoxic to smooth muscle cells (SM3C). Although these 2 systems contain different primary cell types (endothelial cells vs. smooth muscle cells), they are stimulated with the same combination of stimuli (IL-1β, TNF-α, and IFN-γ), suggesting a cell typespecific difference in toxicity mechanisms. As shown in Figure  1 , many of the cytotoxicities observed show a sharp concentration-response relationship. In addition, a few compounds show a reverse concentration effect; they are less cytotoxic at higher concentrations. Compounds showing this effect include fentin, (2-benzothiazolylthio)methyl thiocyanate (TCMTB), captafol, and captan. This reverse concentration effect can be attributed to poor solubility at higher concentrations or possibly biological effects such as induction of a protective response like the phase II enzyme glutathione S-transferase. Solubility was assessed visually on all compounds, and noted precipitations included captafol on initial cell treatment and captan following 24-h incubation.
Reproducibility of BioMAP profiles
To assess the reproducibility of compound activities in these assays, a positive control, colchicine (a tubulin-binding mitotic poison), was included on every assay plate. Figure 2 shows the overlay of the replicate control data in a profile plot. Although the amplitude of biomarker changes for each readout shows variability between replicates (i.e., from plate to plate), the overall profile shape is very consistent and can be used as a measure of reproducibility. Among replicate samples of colchicine, the Pearson correlation coefficients between any 2 replicates were high and ranged from 0.82 to 0.97. Included in the ToxCast chemical library were 3 chemicals each present as 3 independent samples. Correlation coefficients for the 40-µM testing concentration between any 2 replicates had ranges of 0.77 to 0.89 for bensulide, 0.61 to 0.80 for diclofop-methyl, and 0.20 to 0.43 for prosulfuron. Note that prosulfuron had very little significant activity and was thus based on data that largely did not fall outside the 95% significance envelope defined by the solvent controls. Across all assays, average coefficient of variation of the fold-change for the triplicates was 7.2%.
Correlation analysis of ToxCast compound profiles
The BioMAP profiles of ToxCast compounds were compared to one another for similarity by pairwise correlation analysis (see Materials and Methods). Figure 3 shows a visualization of these relationships in a function homology map generated by a comparison of the resulting correlations and display of the correlations by nonlinear projection in 2 dimensions (Sammon mapping, a method of multidimensional scaling that preserves distance and topology of data). 5, 10 Compound similarities that are significant (above a selected threshold) are shown as connected lines. Compound profiles displaying overt cytotoxicity (Fig. 1) were excluded from the map shown.
Analysis of selected ToxCast compounds
The pairwise correlation analysis suggested that ToxCast compounds could be classified into functional groups (clusters in Fig. 3) by BioMAP profiling. Compounds were then further analyzed by comparison to reference BioMAP profiles to evaluate similarity of ToxCast compounds to agents with known mechanisms of action. Examples of similarities and mechanism classes that were discovered by this analysis are listed in Table 2 .
Mitochondrial dysfunction
Compounds with potential to induce mitochondrial dysfunction were identified by their similarity to reference compounds. Reference compounds included oligomycin A, an inhibitor of mitochondrial ATPase; shaoguamycin (complex I inhibitor); myxothiazol (complex III inhibitor); and antimycin A (complex III inhibitor). Oligomycin A was tested in the study along with ToxCast compounds, whereas the profiles for other reference compounds were from a reference database, as described. 12 Figure 4 shows an overlay of the BioMAP profiles for the readouts measured in common for 2 ToxCast compounds representative of this class, pyraclostrobin and trifloxystrobin, along with the profile of the reference, myxathiazol. Pyraclostrobin and trifloxystrobin are strobilurin fungicides known to inhibit mitochondrial function as a mode of their fungicidal action, as do a number of other compounds listed in this class ( Table 2) . 13 Additional compounds with profiles that significantly match this class include the conazole fungicides and others that inhibit sterol biosynthesis as a mode of action, suggesting a connection between sterol biosynthesis and mitochondrial function. Sterol biosynthesis inhibitors in this mechanism class include prochloraz, triadimenol, difenoconazole, fenarimol, and flusilazole. A possible mechanism for this activity may be seen in Saccharomyces cervisiae, where many of the genes that are required for efficient uptake and/or transport of sterols are also required for mitochondrial functions. 14 Reduced mitochondrial membrane sterol content affects the adenine nucleotide transporter in the inner mitochondrial membrane, leading to decreased intramitochondrial adenosine triphosphate (ATP) levels. 15 Vertebrate mitochondria contain P450 enzymes involved in sterol metabolism and may suffer the same fate induced by interference with sterol biosynthesis.
Compounds with potential to induce endoplasmic reticulum stress
Compounds with the potential to induce endoplasmic reticulum stress were identified by their similarity to a group of compounds (A23187, thapsigargin, chlorambucil, sodium azide, cycloheximide, and rotenone), previously identified as having this potential. 12 These compounds are known to interact with diverse targets: for example, chlorambucil is a nitrogen mustard alkylating agent that is used in chemotherapy and covalently modifies many cellular targets in addition to DNA, A23187 is a calcium ionophore, thapsigargan inhibits the SERC ATPase, cycloheximide inhibits acyl transferase II and protein synthesis, sodium azide inhibits mitochondrial complex IV, and rotenone inhibits complex I. The ability of these compounds to induce endoplasmic stress may be through shared secondary targets or common downstream mechanisms involving the generation of reactive species. 12 Several of the chemicals in this group are inhibitors of mitochondrial dysfunction, such as propargite and rotenone, or sodium channel modulators, such as the pyrethroids resmethrin and tefluthrin. Interestingly, the pyrethroids, such as rotenone, have been associated with effects on dopaminergic nerve pathways and could play a role in neurological disorders, including Parkinson's disease. 16, 17 As shown in Figure 5A , the compounds in this class are somewhat diverse, and many show strong concentration-dependent differences in their profiles, consistent with compounds affecting multiple targets. Many of the compounds in this class become overtly cytotoxic to cells at higher concentrations. 
NFκB inhibitors
Compounds with the ability to inhibit the NFκB pathway were identified by similarity to reference NFκB inhibitors, including Ro106-9920 (IκBα ubiquitination inhibitor), BAY 11-7085 (IκBα phosphorylation inhibitor), SC-514 and IKK-2 inhibitor IV (IKK-2 inhibitors), or dimethyl fumarate. 12 As previously described, many chemicals in this group act through covalent modification of NFκB pathway components, resulting in inactivation of the NFκB transcription factor. 10, 18, 19 The dithiocarbamate pesticides such as dazomet, maneb, and metam-sodium appear to have such activity. Dithiocarbamates have also been described as potent inhibitors of NFκB activation in cellular assays. 20 Figure 5B shows a BioMAP overlay of dazomet with dimethyl fumarate.
Elevators of cAMP
ToxCast compounds that upregulate cAMP levels were identified by similarity to cAMP-elevating reference compounds, including the phosphodiesterase IV inhibitors ICI-63197 and rolipram. Figure 5C shows an overlay of the BioMAP profiles of azatrine, cyanazine, and simazine, herbicides of the chlorotriazine class with highly related structures. One notable feature of these profiles is the strong inhibition of TNFα in the BioMAP LPS system and inhibition of PAI-1 levels in the HDF3CGF system, hallmark activities of phosphodiesterase inhibitors that differentiate them from other mechanisms. Atrazine has been demonstrated to inhibit phosphodiesterases and to activate a cyclic-AMP response element reporter gene. 21, 22 Elevated cAMP can induce aromatase expression, causing increased androgen conversion to estrogens in a wide range of tissues. 23 In addition, atrazine was shown to increase activity for an aromatase reporter gene. 22 These activities could explain, in part, the reported endocrine disruptor activity of atrazine resulting from amplification of cAMP, possibly an increase in the cAMP-responsive cellular kinase SGK-1, and nuclear receptor NR5A (SF-1) phosphorylation, a regulator of aromatase gene expression. 22
Microtubule function and estrogen receptor signaling
We have previously described similarity between BioMAP profiles of the estrogen receptor agonist, 17β-estradiol; its metabolite, 2-methoxyestradiol; and microtubule destabilizers. 12 Compounds with similarity to this class were identified by their similarity to colchicine, vinblastine (microtubule destabilizers), 17β-estradiol, and/or 2-methoxyestradiol. Figure 5D shows an overlay of benomyl and fludioxonil with paclitaxel. Benomyl, an antifungal compound, inhibits fungal cell mitosis by binding to microtubules and deforming their structure. It also has been demonstrated to disrupt mammalian cell microtubules and inhibit proliferation and mitosis in HeLa cells with IC 50 of around 5 micromolar, less potent than its activity in fungal cells. 24 This may be responsible for the teratogenic activity of benomyl. 25 The phenylpyrrole fungicide fludioxonil is a natural product analog with an unknown mode of action. 26 However, fludioxonil has been shown to be a clastogen and inducer of polyploidy in Chinese hamster ovary (CHO) cells, activities that are consistent with effects on microtubule function. 27 Teratogenic activity of fludioxonil has not been demonstrated, although whether the parent molecule reaches the developing fetus during developmental toxicity testing is not known.
DISCUSSION
The goal of the ToxCast program is to develop algorithms that predict potential for chemical toxicity using data generated by in vitro bioactivity profiling assays combined with physicochemical properties. Given this ambitious goal of developing a comprehensive approach that will cover a large number of toxicity mechanisms, the profiling assays should encompass a wide range of potential toxicity targets. In part, this requirement is satisfied by high-throughput, biochemical screening assays against a large number of specific molecular targets. 1 However, having assays for all potential individual toxicity targets is not practical. First, knowledge of specific molecular targets of toxicity is incomplete, and the ability to assay all proteins for effects of chemical perturbation is not presently possible. Second, targets of chemical toxicity may be a function of emergent properties of more complex systems such as the cell or intact organism that are not present at the biochemical level. 28 For these reasons, we have included complex cellular assay systems as part of the ToxCast program. The BioSeek cell systems models not only provide such cellular assays but were conducted in primary human cells and thus may provide a more direct link to human health effects than would transformed cell lines typically used in cell-based screening. 29 Eight BioMAP systems were used in the present study, yielding 7 to 14 readouts per system for a total of 87 readouts per compound. The different readouts were not selected for known relevance to toxicity. The selection of readouts and design of the assay systems were directed toward optimal detection and discrimination of diverse target and pathway mechanisms. [4] [5] [6] We did not assume a priori that individual readouts were related to toxicity, but rather our hypothesis was that if the patterns of readouts in these assays can be correlated with diverse mechanisms, some of these may be relevant to toxicity. Despite the large amount of data generated, only a relatively narrow breadth of specific pathophysiology was covered, chiefly vascular and inflammatory biology. However, the ubiquitous nature of critical cell signaling pathways makes it possible that a relatively higher percentage of important toxicological targets are present in these systems. Indeed, past experience with the BioMAP systems demonstrated the ability to discern signatures of activity for disease modulators not directly related to the biology of the specific BioMAP systemfor example, detection of oncology and cardiovascular drug activities in systems designed for inflammatory mechanisms. 4 The key to success under this assumption is a reference library of bioactivity profiles covering important mechanisms of toxicology both to validate the assays and to distinguish mechanisms of action of unknown chemicals. Correlation of bioactivity profiles of a library of pharmacological probes and drugs with signatures generated by screening the ToxCast chemical library provided evidence for mechanisms of potential toxicity for a subset of the library.
Using statistical correlation methods to classify ToxCast chemicals with respect to potential mechanisms of bioactivity revealed at least 5 reasonable matches with profiles in the Bio-Seek database of known compounds. These mechanisms-NFκB inhibitors, cAMP elevation, inducers of mitochondrial dysfunction, endoplasmic reticulum stress, and microtubule inhibitionwere associated with 76 of the 309 unique chemical structures in the library. The types of correlated activities were sometimes related to the intended mechanism of action of the chemical (e.g., pesticides that act through inhibition of mitochondrial respiratory chain function in insects or that destabilize microtubule function in fungus). In other cases, these appear not to be related to intended mechanism of action (e.g., inhibition of NFκB activation, cAMP elevation, or TNF-α secretion). Such effects may or may not reflect toxicity mechanisms. However, they do shed light on mechanisms of bioactivity and potential molecular targets that may prove useful in evaluating the potential toxicity of new chemicals. As we gain greater understanding of the importance of the many different signaling pathways, we will better be able to describe what constitutes a "toxicity pathway" and assess the significance of a chemical's perturbation of it. An important component of this effort is the profiling of compounds of known pharmacological and toxicological effects to measure their ability to modulate these pathways. This will provide validation of the toxicity link of the pathway as well as reference profiles to use for assessing the effects of new chemicals.
It was somewhat surprising that for the most part, chemicals in the ToxCast library generated relatively weak signatures relative to the profiles of the reference pharmacological probes and drugs. All of the compounds in the ToxCast library, consisting largely of pesticide-active ingredients, are bioactive and include many with significant toxicities when tested at high doses in animals. 2 Because bioactivity is a function of dose, it is important to consider the in vitro screening concentration relative to the high-dose, in vivo animal toxicology. It is not clear whether the concentrations used in this profiling effort (i.e., 40 µM top concentration) are a reasonable representation of the effective tissue concentrations associated with lowest effect levels in the in vivo toxicity testing. 2 Toxicity testing in rodents is generally done up to the maximally tolerated dose, and without tissue dosimetry for comparison to concentration response in cell-based, in vitro assays, interpretation remains a challenge. As part of their development, many of these pesticides were designed to be selectively toxic toward pest species, and the weak signatures detected in the BioMAP profiles may reflect this built-in safety margin.
Not all compounds produced statistically significant profiles that closely matched reference compounds in the BioSeek database. There are several possible explanations for this. Compound signatures may reflect poly-pharmacology (i.e., activity against multiple pathways, resulting in confounding signatures of activity that change with testing concentration). Many of the probes or drugs used to generate the reference bioactivity profiles are very selective for specific pathways as an inherent function of their utility as a pharmacological probe or drug. Activities against targets other than the intended may only occur at much higher concentrations due to medicinal chemistry efforts and selective screening. The environmental chemicals, on the other hand, may never have been subject to such engineering and thus could display multiple overlapping profiles at the concentrations tested without one predominant behavior. Alternatively, there may be no reference compounds in the database for accurate comparison. For these cases, use of knowledge about the ToxCast chemicals may provide useful information for future screening using the BioMAP systems. Extensive in vivo toxicity data for the compounds are available in a relational database, 2 and a variety of research data exist in the scientific literature describing modes of action and toxicities for many of the compounds. Further analysis and predictive modeling of the BioMAP profiles of the Toxcast compounds may yield classes of chemicals that can be correlated with toxicity endpoints or mechanisms. This would serve to guide interpretation of future testing of chemicals with little or no toxicity information available.
In addition to the methods of analysis described here, individual endpoints will be included in a more comprehensive collection of data that make up the EPA's ToxCast project. Data from 8 to 10 in vitro assay sources (both cell free and cell based), plus physicochemical properties and chemical structure information, are being used to develop predictive "signatures" of in vivo toxicity as captured in ToxRefDB. A signature in this context is a rule or algorithm against which the in vitro data for a chemical are tested. If the chemical matches the signature, then it is predicted to be toxic for the endpoint being evaluated. We are using a variety of statistical and machine learning methods to mine the ToxCast data. 30 The primary input from the BioMAP data described here are the lowest effective concentrations (LECs), which are the lowest tested concentrations at which a given chemical shows a BioMAP response that is statistically significantly different from background. For each BioMAP system, we exclude components where the LEC is greater than or equal to the LEC at which cytotoxicity is seen for the chemical in the particular BioMAP system.
The future of toxicity testing requires the ability to determine the effects of chemicals on important cellular toxicity pathways in human cells and interpret the significance of any perturbation. 31 Bioactivity profiling of compounds in the primary, human BioMAP cell systems facilitates this for many pathways involved in vascular and inflammatory biology. Coupled with a reference database of many compounds with known toxicities, this approach provides a means to interpret bioactivity in the context of effects on human or rodent pathophysiology. Much work remains to be done in terms of expanding the diversity of toxicological probes for the reference database, expanding the pathophysiology covered by the complex cellular assays, and relating in vitro screening concentrations to actual human exposure levels. In addition, environmental toxicology typically involves effects resulting from exposure to complex mixtures of chemicals. Although not addressed in this study, the pathwaybased approach may allow the ability to discern unexpected effects of exposure to mixtures that would only be apparent in complex cell biology models. Overall, this approach represents an important first step in the ability to use primary human cells in vitro as model systems for evaluating environmental chemicals for risks to human health.
